Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on BriaCell Therapeutics (BCT – Research Report), boosting the price target to $32.00.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Emily Bodnar’s rating is based on promising initial results from BriaCell Therapeutics’ Bria-OTS Phase 1 study. The first patient treated showed a complete resolution of a lung metastasis after only two months on the lowest dose, indicating the potential effectiveness of the therapy even at low doses. This study highlights the personalized nature of Bria-OTS, which could match a vast majority of breast cancer patients, enhancing its appeal.
Moreover, the company plans to expand the Bria-OTS trial to other cancers, such as prostate, lung, and melanoma, utilizing its adaptable technology platform. Additionally, after a reverse stock split and updated financial model, the price target was adjusted to $32, reflecting confidence in the company’s strategic direction and future potential. These factors collectively underpin the Buy rating for BriaCell Therapeutics.